382 related articles for article (PubMed ID: 28340881)
1. CD30
Sauder MB; O'Malley JT; LeBoeuf NR
Hematol Oncol Clin North Am; 2017 Apr; 31(2):317-334. PubMed ID: 28340881
[TBL] [Abstract][Full Text] [Related]
2. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
3. CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: a report of two cases and analysis of CD30 expression.
Gill K; Ariyan C; Wang X; Brady MS; Pulitzer M
J Surg Oncol; 2014 Sep; 110(3):258-64. PubMed ID: 24891295
[TBL] [Abstract][Full Text] [Related]
4. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
Liu HL; Hoppe RT; Kohler S; Harvell JD; Reddy S; Kim YH
J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383
[TBL] [Abstract][Full Text] [Related]
5. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
Wieser I; Oh CW; Talpur R; Duvic M
J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172
[TBL] [Abstract][Full Text] [Related]
6. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
7. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases.
Hagiwara M; Tomita A; Takata K; Shimoyama Y; Yoshino T; Tomita Y; Nakamura S
Pathol Int; 2012 Apr; 62(4):264-70. PubMed ID: 22449230
[TBL] [Abstract][Full Text] [Related]
9. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
[TBL] [Abstract][Full Text] [Related]
10. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
[TBL] [Abstract][Full Text] [Related]
11. CD30+ lymphoproliferative disorder with spindle-cell morphology.
Martires KJ; Cohen BE; Cassarino DS
J Cutan Pathol; 2016 Nov; 43(11):1041-1044. PubMed ID: 27433975
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
Vonderheid EC; Sajjadian A; Kadin ME
J Am Acad Dermatol; 1996 Mar; 34(3):470-81. PubMed ID: 8609262
[TBL] [Abstract][Full Text] [Related]
13. Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2017; 21(6):507-512. PubMed ID: 28614957
[TBL] [Abstract][Full Text] [Related]
14. Lymphomatoid papulosis: an update and review.
Martinez-Cabriales SA; Walsh S; Sade S; Shear NH
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):59-73. PubMed ID: 31494989
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.
Montes-Moreno S
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):136-139. PubMed ID: 38010388
[TBL] [Abstract][Full Text] [Related]
16. CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis.
Aoki M; Niimi Y; Takezaki S; Azuma A; Seike M; Kawana S
Br J Dermatol; 2001 Jul; 145(1):123-6. PubMed ID: 11453920
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
Liang X; Smoller BR; Golitz LE
J Cutan Pathol; 2002 Sep; 29(8):459-64. PubMed ID: 12207739
[TBL] [Abstract][Full Text] [Related]
18. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W
Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue.
Guitart J; Querfeld C
Semin Diagn Pathol; 2009 Aug; 26(3):131-40. PubMed ID: 20043512
[TBL] [Abstract][Full Text] [Related]
20. Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.
Stowman AM; Hsia LL; Kanner WA; Mahadevan MS; Bullock GC; Patterson JW
Int J Dermatol; 2016 Feb; 55(2):e62-71. PubMed ID: 26266670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
